Bio Green Med Solution, Inc. SEC filings BGMS

Bio Green Med Solution, Inc. has 1,000 filings in SEC EDGAR's recent list, going back to Mar 31, 2010. Its latest annual report, Form 10-K, was filed on Mar 30, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 14, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Nov 4, 2026 (listing notice). The company's fiscal year ends on December 31.

Bio Green Med Solution, Inc. SEC filings
Form Description Filed Period
DEF 14A Proxy statement Apr 27, 2026 Apr 27, 2026
DEFA14A Additional proxy material Aug 25, 2025 —
DEF 14C Information statement Jul 7, 2025 Jul 7, 2025
DEFA14A Additional proxy material Jun 25, 2025 —
PRE 14C Filing Jun 25, 2025 Jun 25, 2025
DEF 14C Information statement May 23, 2025 May 23, 2025
PRE 14C Filing May 13, 2025 May 13, 2025
DEF 14A Proxy statement Apr 24, 2025 Apr 24, 2025
DEF 14C Information statement Apr 3, 2025 Apr 3, 2025
PRE 14C Filing Mar 24, 2025 Mar 24, 2025
DEF 14A Proxy statement Jan 21, 2025 Feb 6, 2025
PRE 14A Preliminary proxy statement Jan 8, 2025 Jan 7, 2025
DEFA14A Additional proxy material May 8, 2024 —
DEF 14A Proxy statement May 8, 2024 Jun 21, 2024
DEF 14A Proxy statement Nov 14, 2023 Dec 8, 2023
PRE 14A Preliminary proxy statement Nov 2, 2023 Dec 14, 2023
DEFA14A Additional proxy material Apr 28, 2023 —
DEF 14A Proxy statement Apr 28, 2023 Jun 13, 2023
DEFA14A Additional proxy material Apr 28, 2022 —
DEF 14A Proxy statement Apr 26, 2022 Jun 14, 2022
DEFA14A Additional proxy material Apr 29, 2021 —
DEF 14A Proxy statement Apr 29, 2021 Jun 15, 2021
DEFA14A Additional proxy material May 12, 2020 —
DEF 14A Proxy statement May 12, 2020 Jun 25, 2020
DEF 14A Proxy statement Sep 27, 2019 Oct 28, 2019
PRE 14A Preliminary proxy statement Sep 17, 2019 Oct 28, 2019
DEFA14A Additional proxy material Apr 10, 2019 —
DEF 14A Proxy statement Apr 10, 2019 May 29, 2019
DEFA14A Additional proxy material Apr 12, 2018 —
DEF 14A Proxy statement Apr 12, 2018 May 31, 2018
DEFA14A Additional proxy material Apr 12, 2017 —
DEF 14A Proxy statement Apr 12, 2017 May 30, 2017
DEFA14A Additional proxy material Apr 12, 2016 —
DEF 14A Proxy statement Apr 11, 2016 May 26, 2016
PRE 14A Preliminary proxy statement Mar 30, 2016 May 26, 2016
DEF 14A Proxy statement Apr 7, 2015 May 22, 2015
DEFA14A Additional proxy material Apr 7, 2014 —
DEF 14A Proxy statement Apr 2, 2014 May 22, 2014
DEFA14A Additional proxy material Apr 5, 2013 —
DEF 14A Proxy statement Apr 3, 2013 May 22, 2013
DEFA14A Additional proxy material May 15, 2012 —
DEF 14A Proxy statement Apr 19, 2012 May 23, 2012
PRE 14A Preliminary proxy statement Apr 6, 2012 May 23, 2012
DEF 14A Proxy statement Apr 27, 2011 May 24, 2011
DEFA14A Additional proxy material Oct 28, 2010 —
DEFA14A Additional proxy material Oct 8, 2010 —
DEF 14A Proxy statement Sep 21, 2010 Oct 4, 2010
DEF 14A Proxy statement Apr 23, 2010 May 25, 2010

Showing 48 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.

Company profile

Industry
Wholesale-Durable Goods, NEC (SIC 5099)
Listed as
BGMS (Nasdaq), BGMSP (OTC)
Fiscal year ends
December 31
Incorporated in
DE
Headquarters
Berkeley Heights, NJ
SEC filer status
Non-accelerated filer, Smaller reporting company
SEC CIK
1130166
Former names
Cyclacel Pharmaceuticals, Inc. (until Sep 12, 2025); XCYTE THERAPIES INC (until Mar 24, 2006)

Other Wholesale-Durable Goods, NEC companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.